Cancer Drug Delivery Systems Based on the Tumor Microenvironment

Yasuhiro Matsumura, MD, PhD, Director, Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, JapanDavid Tarin, MD, PhD, FRCPath, Professor of Pathology, UC San Diego Moores Cancer Center, University of California, USA

• Preface.- Part I Cancer pathophysiology.- 1. The Cancer Stroma and its relevance to tumor survival.- 2. Cancer and blood coagulation .- 3. Tumor Blood Vessels as targets for cancer therapy.- 4. Stromal barriers within the tumor microenvironment and obstacles to nanomedicine.- Part II Antibody drug conjugates (ADC).- 1. Recent progress in linker technology for antibody-drug conjugates: Methods for connection and release.- 2. Preclinical studies of ADC therapy for solid tumors.- 3. ADCs on the market and in clinical development.- Part III Hybrid techniques of active and passive targeting.- 1. Micelles conjugated with a pilot molecule.- 2. Liposomes conjugated with a pilot molecule.- 3. Multifunctional Envelope-type Nano Devices (MEND) for cancer therapy.- Part IV Cancer stromal targeting (CAST) therapy and diagnosis.- 1. Principle of CAST.- 2. CAST therapy.- 3. CAST diagnosis.- Part V The Current Status of Cancer Drug Delivery Systems and Future Directions.- Index.